Gilead Offers Its Newest Hiv Drug Candidate To Patent Pool For Low-Cost Production
Gilead Sciences Is Licensing Its Newest Hiv Drug Candidate, Bictegravir, To The U.N.-Backed Medicines Patent Pool, Meaning It Will Be Produced And Sold At A Lower Cost In 116 Low- And Middle-Income Countries Once It Is Approved.Gilead Said It Will Include The Hiv-1 Candidate In Its Existing Agreements With Generic Drugmakers Sun Pharmaceutical Industries, Strides Shasun, Mylan And Sequent Scientific, As A Single Agent Or In Fixed-Dose Combinations With Other Hiv Medicines,
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!